Iminothiazolidinones as inhibitors of HCV replication

US7183302B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jeffrey Lee Romine · Meriden, US
• Scott W. Martin · Middletown, US
• Lawrence B. Snyder · Killingworth, US
• Michael H. Serrano-Wu · Cambridge, US
• Milind Deshpande · Madison, US
• Darren Whitehouse · Westbrook, US
• Julie A. Lemm · Durham, US
• Donald O'Boyle · Killingworth, US
• Min Gao · 安丰镇, CN
• Richard Colonno · Buckingham, GB

Key dates

• Filing date: Aug 8, 2003
• Grant date: Feb 27, 2007
• Expiry date: Mar 5, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structure of formula I are describedwherein R, R′, R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.